A 12-week randomized trial demonstrated: Average weight loss of 2.6 kg in AOD-9604 group (1 mg/day) versus 0.8 kg in placebo group Preferential reduction in abdominal and visceral fat deposits No adverse effects on carbohydrate metabolism or insulin sensitivity Non-dose-dependent effects, with higher doses (10 mg/day) producing less weight loss than lower doses However, a subsequent 24-week Phase III trial with 502 subjects incorporating intensive diet and exercise showed no statistically significant weight loss compared to placebo, leading to development termination in 2007
The beyond-use date assigned by a compounding pharmacy is typically 28 to 90 days from the date of preparation, depending on the formulation type and the pharmacy's own stability testing
Accelerates Post-Surgery Recovery From cosmetic to orthopedic procedures, BPC-157 supports faster tissue regeneration , reduced scar formation , and wound healing post-surgery
When 5-amino-1MQ is handling the metabolic rate enhancement through NNMT inhibition, maximal tirzepatide dosing becomes less critical the stacks synergy comes from dual-pathway activation, not from maximizing either single pathway
The Bottom Line AOD 9604 is an intriguing peptide therapy that may help support fat metabolism and healthy aging, particularly for adults over 50 dealing with stubborn weight gain and metabolic changes
